UOC
ITRM

UBS O'Connor’s Iterum Therapeutics ITRM Stock Holding History

UBS O'Connor’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,867
Closed -$124K – 906
2021
Q1 		$124K Hold
5,867
– – ﹤0.01% 729
2020
Q4 		$87K Hold
5,867
– – ﹤0.01% 564
2020
Q3 		$92K Hold
5,867
– – ﹤0.01% 295
2020
Q2 		$105K Sell
5,867
-46
-0.8% -$1.82K ﹤0.01% 368
2020
Q1 		$240K Hold
5,913
– – ﹤0.01% 293
2019
Q4 		$399K Hold
5,913
– – 0.01% 260
2019
Q3 		$523K Hold
5,913
– – 0.01% 236
2019
Q2 		$610K Buy
+5,913
New +$657K 0.01% 191
2019
Q1 		– Sell
-6,601
Closed -$496K – 84
2018
Q4 		$496K Sell
6,601
-66
-1% -$6.25K 0.02% 198
2018
Q3 		$670K Hold
6,667
– – 0.02% 222
2018
Q2 		$1.09M Buy
+6,667
New +$1.2M 0.02% 204

Other funds holding ITRM

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
KFS
Kelly Financial Services Braintree, Massachusetts $467M AUM 21.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
QI
QS Investors New York $8.47B AUM 30.71% 1-Year Est. Return
FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $3.61B AUM 18.46% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS O'Connor's ITRM Position: Q2 2021 in Review

UBS O'Connor sold out of Iterum Therapeutics (ITRM) in Q2 2021, closing a stake of 5,867 shares — an estimated $124K sold.

UBS O'Connor first reported a position in ITRM in Q2 2018 and held it in 11 quarters. The position peaked at $1.09M in Q2 2018. 44 funds tracked by Wall St. Rank hold ITRM as of Q2 2021.

  • UBS O'Connor reported no remaining Iterum Therapeutics position as of Q2 2021 after selling out during the quarter.
  • UBS O'Connor sold 5,867 Iterum Therapeutics shares in Q2 2021, an estimated $124K.
  • UBS O'Connor first reported a position in Iterum Therapeutics in Q2 2018 and held it in 11 quarters.
  • UBS O'Connor's Iterum Therapeutics position peaked at $1.09M in Q2 2018.
  • 44 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2021.

Based on UBS O'Connor's 13F filing for Q2 2021, filed 13 Aug 2021.